doc.ai, a digital health company designed for a new generation of medical research, announced the opening of an Epilepsy Digital Health Trial focused on how Artificial Intelligence (A.I.) can help identify the right treatment for the right patient at the right time.
The study, led by principal investigator Robert Fisher, MD PhD, professor of neurology and neurological sciences at the Stanford University School of Medicine and director of the Stanford Epilepsy Center, will deploy and test A.I. to develop a predictive model for treatment.
The at-home, HIPAA-compliant and IRB-approved Digital Health Trial seeks to enroll up to 1,000 eligible participants between September 2019 and September 2020. Once enrolled via the doc.ai app, participants will keep an online diary tracking their seizure episodes and side effects of medication for three months. Along with the self-reported data, the study will collect and analyze patients’ health data, including an array of personal-omics information, such as the genome (DNA test provided by Kailos), phenome to capture physical traits, physiome for exercise and activity tracking, pharmacome or medication tracking and finally, the exposome, which includes environmental exposures. The trial also leverages doc.ai A.I. technologies such as natural language processing for participants to capture a photograph of their medication bottles for automatic import.